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Acute Respiratory Distress Syndrome: Pathophysiology and
Therapeutic Options
Charalampos Pierrakosa, Menelaos Karanikolasb, Sabino Scollettac, Vasilios Karamouzosd,
Dimitrios Velissarise, f

Abstract
Acute Respiratory Distress Syndrome (ARDS) is a common entity
in critical care. ARDS is associated with many diagnoses, including
trauma and sepsis, can lead to multiple organ failure and has high
mortality. The present article is a narrative review of the literature
on ARDS, including ARDS pathophysiology and therapeutic options currently being evaluated or in use in clinical practice. The
literature review covers relevant publications until January 2011.
Recent developments in the therapeutic approach to ARDS include refinements of mechanical ventilatory support with emphasis
on protective lung ventilation using low tidal volumes, increased
PEEP with use of recruitment maneuvers to promote reopening of
collapsed lung alveoli, prone position as rescue therapy for severe
hypoxemia, and high frequency ventilation. Supportive measures
in the management of ARDS include attention to fluid balance, restrictive transfusion strategies, and minimization of sedatives and
neuromuscular blocking agents. Inhaled bronchodilators such as
inhaled nitric oxide and prostaglandins confer short term improvement without proven effect on survival, but are currently used in
many centers. Use of corticosteroids is also important, and appropriate timely use may reduce mortality. Finally, extra corporeal

Manuscript accepted for publication December 1, 2011
a

Intensive Care Department, Brugmann University Hospital, Brussels
1030, Belgium
b
Department of Anesthesiology, Washington University School of
Medicine, St. Louis, Missouri, USA
c
Department of Surgery and Bioengineering, Unit of Cardiothoracic
Anesthesia and Intensive Care, University of Siena, Italy
d
Department of Internal Medicine, University Hospital of Patras, Rio,
Greece
e
Department of Anesthesiology and Critical Care Medicine, University
Hospital of Patras, Rio, Greece
f
Corresponding author: Dimitrios Velissaris.
Email: dimitrisvelissaris@yahoo.com
doi:10.4021/jocmr761w

oxygenation methods are very useful as rescue therapy in patients
with intractable hypoxemia, even though a survival benefit has not,
to this date been demonstrated. Despite intense ongoing research
on the pathophysiology and treatment of ARDS, mortality remains
high. Many pharmacologic and supportive strategies have shown
promising results, but data from large randomized clinical trials are
needed to fully evaluate the true effectiveness of these therapies.
Keywords: ARDS; Pathophysiology; Treatment

Introduction
In 1821, Laennec described a new syndrome characterized
by pulmonary edema without heart failure [1]. Subsequently,
several terms, such as “double pneumonia”, “shock lung”
and “post traumatic lung” have been used to describe this
syndrome. The term “Acute Respiratory Distress Syndrome”
was first used in 1967 to describe a distinct clinical entity
characterized by acute abnormality of both lungs [2].
In 1994, the American-European Consensus Conference
on ARDS established criteria for the diagnosis of ARDS.
These criteria include acute onset, bilateral lung infiltrates,
no evidence of elevated left atrial pressure and arterial oxygen tension to inspired oxygen fraction (PaO2/FiO2) less
than 200. The diagnosis of ARDS requires all these features.
However, as these clinical criteria do not always correlate
well with diffuse alveolar damage, which is the typical pathologic ARDS feature, ARDS remains a syndrome associated
with multiple diagnoses [3], rather than a disease in itself.
Despite substantial progress in understanding ARDS
pathophysiology, ARDS remains a major clinical problem,
and mortality is still as high as 40 - 46%. The incidence of
ARDS in the Intensive Care Unit (ICU) ranges between 4%
to 9% depending on patient age and study population [4].

Pathophysiology
Increased capillary permeability is the hallmark of ARDS.
Damage of the capillary endothelium and alveolar epitheli-
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um in correlation to impaired fluid remove from the alveolar
space result in accumulation of protein-rich fluid inside the
alveoli, thereby producing diffuse alveolar damage, with release of pro-inflammatory cytokines, such as Tumor Necrosis Factor (TNF), IL-1 and IL-6 [5]. Neutrophils are recruited
to the lungs by cytokines, become activated and release toxic
mediators, such as reactive oxygen species and proteases [6].
Extensive free radical production overwhelms endogenous
anti-oxidants and causes oxidative cell damage [7].
Inflammation due to neutrophil activation is key in the
pathogenesis of ARDS. Fundamental transcription abnormalities, involving NF-kappa B that is required for transcription of genes for many pro-inflammatory mediators,
are present in the lungs of ARDS patients [8]. In addition,
other factors such as endothelin-1, angiotensin-2 and phospholipase A-2 increase vascular permeability and destroy
micro-vascular architecture, enhancing inflammation and
lung damage. In conclusion, as several different pathways
are involved in ARDS development, no single biomarker can
predict outcome in ARDS patients [9].
Computed Tomography studies in the 1980s helped us
understand the pathophysiologic alterations in the lungs of
ARDS patients [10]. In addition, as lung compliance correlates with the degree of the normally ventilated tissue, lung
compliance decreases in ARDS because of decreased lung
size, rather than because of lung stiffness, and this hypothesis introduced the concept of ”baby lung” in ARDS [11].
Pulmonary hypertension (PH) is widely recognized as
a characteristic feature of ARDS [12]. PH etiology includes
parenchymal destruction and airway collapse, hypoxic pulmonary vasoconstriction, presence of other pulmonary vasoconstrictors and vascular compression [13].
The initial phase of fluid accumulation is followed by a
proliferation phase characterized by resolution of pulmonary
edema, proliferation of type II alveolar cells, fibroblasts and
myofibroblasts, and new matrix deposition. This phase starts
early (within 72 h) in ARDS, and lasts for more than 7 days.
Factors influencing the progression to fibro-proliferation vs.
resolution and reconstitution of normal pulmonary parenchymal architecture are poorly understood [14], but patients
who develop pulmonary fibrosis exhibit deterioration of pulmonary compliance, progressive hypoxia and ventilator dependence, and increased mortality (> 57%) [15].
Multiple Organ Failure (MOF) is the leading cause
of death in ARDS, but the pathophysiologic link between
ARDS and MOF is not well defined [16]. However, based
on existing data it is not clear whether ARDS is the manifestation of a disease, or it is a disease that causes the MOF
syndrome.

Treatment
Improved understanding of ARDS pathophysiology and ad-
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vances in technology have introduced new treatments and
improved therapeutic strategies. The following paragraphs
discuss recent developments in the therapeutic approach to
ARDS.
Low tidal volume ventilation
The concept of “baby lung” was introduced in 1980s by
Gattinoni et al and generated interest in the use of low tidal
volume ventilation as therapeutic strategy in ARDS. Several
animal studies showed that ventilation with large tidal volumes and high inspiratory pressures resulted in development
of hyaline membranes and inflammatory infiltrates in the
lungs, and development of respiratory failure [17].
In the late 1990s four randomized controlled trials
(RCTs) evaluated the potential benefit of low tidal volume
ventilation in ARDS [18-21]. Although all four studies had
limited power, one study by Amato et al [21] demonstrated
that the low tidal volume group had higher survival, higher
rate of weaning from mechanical ventilation and reduced
rate of barotrauma.
Because of conflicting results from these studies, the
National Heart Lung and Blood Institute ARDS Network
conducted a multicenter RCT on 861 ARDS patients [22],
comparing two group of patients ventilated with low vs. high
tidal volumes. In-hospital mortality was significantly lower
and the number of days without mechanical ventilation was
significantly higher in the low tidal volume group. Although
this study has been criticized for the high difference of tidal
volume between groups, it demonstrated that high tidal volumes should be avoided, and underlined the importance of
maintaining low plateau pressures, with 30 cm H2O as an
acceptable cut-off.
Low tidal volume ventilation is generally well tolerated
and it has not been associated with clinically important adverse outcomes, except for hypercapnic respiratory acidosis
in some patients. In conclusion, hypercapnia and respiratory
acidosis are expected consequences of low tidal volume ventilation. However, there is no evidence that hypercapnia is
harmful in ARDS patients, and it may in fact confer some
protection against ventilator-associated lung injury.
PEEP
PEEP is an essential component of mechanical ventilation
for patients with ARDS, as it was early observed that PEEP
greatly improves oxygenation in ARDS patients. High PEEP
levels may open collapsed alveoli and decrease intrapulmonary shunt. Additionally, ventilation-induced alveolar injury
is reduced by decreasing alveolar over-distention, because
the volume of each subsequent tidal breath is shared by more
open alveoli [23]. On the other hand, high PEEP levels may
decrease repetitive alveolar opening and closing during the
respiratory cycle, thereby promoting lung injury [24].
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Three RCTs have evaluated modest vs. high levels of
PEEP in patients with ARDS. The NHLB ARDS Network
conducted the ALVEOLI trial (Assessment of Low tidal Volume and Elevated end expiratory pressure to Obviate Lung
Injury) [25]. This study showed improved PaO2/FiO2 ratio
but no benefits with regards to survival or duration of mechanical ventilation in the high PEEP group. Several years
later, the Canadian Critical Care Trials Group performed a
similar study to determine whether the combination of low
tidal volume ventilation with high PEEP could improve mortality to a greater extent compared to low tidal ventilation
alone [26]. Results of this study showed reduced need for
other rescue therapies such as prone position or NO, but did
not show any benefit in survival.
In conclusion, based on published data, high levels of
PEEP do not seem to confer any benefit with regards to mortality in ARDS. Because ARDS patients are a heterogeneous
population, the apparent absence of benefit from high levels
of PEEP could be due to the beneficial effects of high PEEP
in some ARDS patients being offset by detrimental effects in
other patients [27]. However, data from the RCTs mentioned
above suggest that high PEEP levels improve lungs function
without any adverse effect on mortality [28].
Recruitment maneuvers
A recruitment maneuver is a transient increase of trans-pulmonary pressure intended to promote reopening of collapsed
alveoli [29]. Techniques described for recruitment maneuvers include sustained high-pressure inflation and increased
PEEP, with concurrent reduction of tidal volume [30], but
it is not clear if any maneuver is superior to others. Several
studies have shown improved gas exchange with recruitment
maneuvers, but no RCT has shown benefit on ARDS mortality [31] and a recent systematic review by Fan et al [32]
showed that hypotension and decreased saturation occur in
12% and 8% of patients respectively during or after such maneuvers. Based on currently available data, although routine
recruitment maneuvers are not recommended in ARDS, such
maneuvers can dramatically improve oxygenation in certain
patients, and should be considered as rescue therapy in patients with life-threatening refractory hypoxia [33].
Prone position
Prone positioning has been used in ARDS for over 30 years.
In 1976 Piehl et al. reported improved oxygenation in ARDS
patients when they were turned to the prone position [34].
Since then, several observational studies on ARDS have
found similar results, and improvement in oxygenation can
sometimes be dramatic [35]. Mechanisms proposed to explain the observed beneficial effects of prone positioning
include increased chest wall elastance decreased compression of lung tissue in the dependent regions and recruitment
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of alveoli, more homogeneous ventilation due to decreased
ventilation-perfusion inequalities and reduced ventilator induced lung injury [36].
Four RCTs have investigated the effect of prone positioning on outcome. The first trial by the Prone-Supine Study
group randomized 304 patients with a wide range of severity
of acute lung injury [37].Patients remained prone for 7 h/
day on average, for up to 10 days, but there was no effect on
survival. Three years later, Guerin et al conducted a similar
multicenter study [38]: patients remained prone for about 8
h/day, and prone positioning continued until clinical criteria
for improvement were met, but this study also did not show
a reduction in mortality. Two subsequent RCTs attempted to
correct some shortcomings of the earlier study: they only included patients with ARDS, and patients remained prone for
most of the day (about 20 h). The first RCT by Mancebo et
al was terminated prematurely, after only including 142 patients, because of problems with patient recruitment [39]. A
more recent multicenter RCT by Taccone et al, included 344
patients [40], and showed significantly increased frequency
of adverse events (airway obstruction, hypotension, vomiting, accidental extubation) in patients treated with prone
position. Neither of the last two studies showed any survival benefit using the prone position in patients with severe
ARDS.
In conclusion, existing data do not support routine use of
the prone position in ARDS. However, because all published
studies have shown improved oxygenation, prone positioning is an attractive rescue treatment for ARDS patients with
severe hypoxemia, even though a survival benefit has never
been demonstrated.
High-frequency ventilation
The idea of high frequency ventilation (HFV) is to provide
tidal volumes below that of anatomic dead space at high frequency (> 60 breaths per minute). Compared to conventional
mechanical ventilation, mean airway pressure is higher [41].
Two studies, by Hamilton and Chan, showed reduced risk for
barotrauma and lung over-distention, after performing high
frequency ventilation [42, 43]. High frequency ventilation
can be applied by different modes, such as high-frequency
percussive ventilation, high-frequency jet ventilation and
high-frequency oscillatory ventilation (HFOV) [44]. In the
absence of studies showing superiority of one method over
another, HFOV is the HFV method used more often in adult
critical care [43].
In HFOV very small tidal volumes (1 - 4 ml/kg) are delivered at high frequency (3 - 15 Hz) by an oscillatory pump
[45]. However, the use of HFOV as rescue therapy in patients with refractory hypoxia remains controversial. There
are two RCTs comparing HFOV with conventional mechanical ventilation. The first RCT by Derdak et al found a trend
for decreasing 30-day mortality [46] even though relatively

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press™ | www.jocmr.org

9

Pierrakos et al

J Clin Med Res • 2012;4(1):7-16

high tidal volume was used in the control group. The second
RCT by Bollen et al was terminated prematurely because
of slow enrollment, but found an opposite trend in mortality [47]. Two meta-analyses also had conflicting results. The
first one included only 2 RCTs comparing HFOV vs. conventional ventilation, and did not find any mortality reduction or improvement of oxygenation [48]. However, a more
recent study by Sud et al included 8 RCTs and found reduced
30-day mortality with HFOV compared to conventional ventilation [49]. In conclusion, the role of HFOV in ARDS is
not well defined, and deserves further study from well designed RCTs.
Supportive treatment of ARDS
Fluid management
Early data indicate that increased fluid administration is
correlated with worse outcome in ARDS, whereas negative
fluid balance was associated with better outcome [50]. The
ARDS network conducted a RCT with 1000 patients randomized to receive conservative or liberal fluid administration. The conservative strategy group showed improved lung
function and shortened duration of mechanical ventilation,
but there was no difference in non pulmonary organ failures
and 60-day mortality.
Transfusions
Allogenic blood transfusion is associated with detrimental
immuno-modulatory effects that may result in ARDS [51].
Consequently, conservative transfusion strategies may decrease the incidence of ARDS.
Sedation
Several studies have shown that newer ventilation strategies using low tidal volume and high levels of PEEP do not
require high doses of sedation [52]. Furthermore, evidence
suggests that use of sedatives may increase duration of mechanical ventilation and ICU length of stay and may even be
associated with higher mortality [53]. In addition, there is
evidence that spontaneously breathing ARDS patients have
improved cardiopulmonary function, presumably by recruiting non ventilated lung units [54]. Therefore, based on current evidence, avoidance or minimization of sedation and
paralysis is preferred in ARDS.
Neuromuscular blocking agents
Administration of neuromuscular blocking agents (NMBA)
in addition to sedation can result in improvement in severe
hypoxemia, because paralysis improves patient-ventilator
synchronism and reduces oxygen consumption [55]. Muscle
10

relaxation may also improve chest wall compliance. NMBAs
may also have anti-inflammatory effects that could decrease
the inflammation associated with ARDS. However, because
there is evidence that NMBAs increase the risk of acquired
neuromuscular weakness, thereby making weaning from
mechanical ventilation more difficult, and may even increase
mortality [56].
Nutrition
Two RCTs [57, 58] and a meta-analysis by Puntes-Arruda
et al [59] showed that administration of enteral nutrition
containing high concentrations of eicosapentanoic acid and
γ-linoleic acid and ω-3 fatty acids increased oxygenation and
decreased ICU stay and 28-day mortality in ARDS.
Pharmacologic agents
Vasodilators
Because diffuse pulmonary vasoconstriction is part of ARDS
pathophysiology, selective vasodilatation of well ventilated
areas seems an attractive method to improve gas exchange in
ARDS patients.
Inhaled nitric oxide (iNO) causes vasodilation of ventilated lung units and redistribution of pulmonary blood flow
away from non-ventilated lung areas, without adverse systemic hemodynamic effects. Four RCTs evaluated the effects
of iNO and showed transient improvement in oxygenation
[60-63], but no improvement in mortality. Similarly, one
meta-analysis found transient oxygenation improvement but
no survival benefit with iNO [64]. Consequently, iNO may
be useful as short-term rescue therapy in patients with severe
hypoxemic respiratory failure.
Inhaled prostacycline is another selective pulmonary
vasodilator. Importantly, liposomal PGE1 influences neutrophil function and decreases neutrophil accumulation
and lung leak. Although inhaled prostacycline improves
oxygenation, it has not been shown to reduce duration of
mechanical ventilation or mortality in ARDS patients [65].
Despite the lack of sufficient data supporting the use of
prostacycline as alternative to iNO, prostacycline is increasingly used as pulmonary vasodilator, because of the high
cost of iNO [66].
Vasoconstrictors
Vasoconstrictors can improve oxygenation in ARDS patients
by decreasing intrapulmonary shunt. Phenylephrine [67] and
almitrine [68] have been used in small studies, mainly as
adjuncts during administration of NO. B-blockers have also
been shown to increase arterial oxygenation in patients with
ARDS [69]. However, the role of these agents in ARDS has
not been adequately evaluated, and deserves further study.
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Anti inflammatory agents
The interaction between nuclear factor-kappa B (NF-kB)
and glucocorticoid receptor alpha (GRa) is a key mechanism
regulating the progression of systemic and pulmonary inflammation in ARDS [70]. The ability of GC-GRa to downregulate NF-kB activation is critical for the resolution of systemic and pulmonary inflammation in ARDS [71]. Although
several studies showed that corticosteroids confer no benefit
and may even cause harm [72], corticosteroids are still used
in clinical practice.
Timing of corticosteroid administration and duration of
therapy may be important, and should be taken into consideration. A RCT conducted by the ARDS Network, randomized 180 patients with persistent (> 7 days) ARDS, to receive
methylprednisolone (2 mg/kg/d) or placebo for 21 days, and
showed improved oxygenation and more ventilator-free days
in the methylprednisolone group, but no significant improvement in mortality [73]. Another RCT evaluated early corticosteroid administration, and showed that methylprednisolone
administration (1mg/kg/d) [74] less than 72 after the onset of
ARDS reduced mortality. However, these results should be
interpreted with caution, because this study included a large
number of patients with septic shock.
Conflicting data exist concerning the correlation between corticosteroids and ICU neuromyopathy. A sub-analysis of study survivors did not show any association between
randomization to corticosteroids and increased risk of neuromyopathy [75]. In conclusion, the relationship between corticosteroids and ICU neuromyopathy is an important issue
that deserves further study [76].
Several other anti-inflammatory factors like Ibuprofen
[77], ketoconazole [78], neutrophil elastase inhibitors (ONO
5046) [79], NF-KB inhibitors [80], recombinant soluble
complement receptor-1 [81], and liposomal prostaglandin E1
[82] have been evaluated in ARDS patients without success.
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[87] have been evaluated, but none of them has been shown
to be effective for treatment of ARDS.
Extracorporeal techniques
Extracorporeal membrane oxygenation (ECMO) has been
studied since 1970s as a method for supporting gas exchange
in patients failing conventional ventilation [88]. A RCT conducted in 1979 showed that ECMO use had no effect on longterm survival of ARDS patients [89]. Nowadays, ECMO is
used to support oxygenation of patients with severe ARDS,
thereby allowing use of decreased ventilator settings (tidal
volume, respiratory rate, FiO2), in an attempt to minimize
ventilator induced lung injury.
In a more recent study 180 patients with severe ARDS
were randomized to support by ECMO vs. conventional
treatments. This study showed significantly improved survival (63% vs. 47%, P = 0.03) at 6 months in the ECMO
group [90]. Although no definite conclusions can be drawn
from this study [91], the results of this study suggest that
ECMO can be used as a rescue therapy in cases of very severe ARDS.
Extracorporeal CO2 removal (ECCO2R) is an alternative device that uses veno-venous circuit for removal of
CO2 at much lower extracorporeal flow rates compared to
ECMO. A RCT conducted before the year 2000 used ECCO2R and showed no effect on mortality [92]. In another
study ECCO2R was combined with low frequency positive
pressure ventilation (2 - 3 b/min), and showed improvement
in lung mechanics [93]. Overall, extracorporeal support
technologies produce significant temporary improvement in
ARDS patients with severe respiratory dysfunction, but this
improvement does not seem to affect outcome. New, well
conducted clinical studies are needed to better evaluate the
role of ECMO and ECCO2R on survival in ARDS.

Beta agonists

Mortality

There are substantial evidences that b2-agonists may play a
potential role in the treatment of patients with ARDS. B2 agonists have been found to have anti-inflammatory effects by
direct influence on neutrophil function and by reducing the
secretion of several pro-inflammatory cytokines. Additionally, b2-agonists can reduce the endothelial permeability and
stimulate the fluid clearance from the lungs [83]. In a small
RCT using the thermodilution method (PiCCO), intravenous
salbutamol (15 μg/kg/h) use for seven days reduced extravascular lung water compared to placebo [84]. The effects
of inhaled b-agonists have not, to this date, been adequately
evaluated, but will be investigated in an ongoing study conducted by ARDS network (NCT00434993)
Several other pharmacological agents, including glutathione lisofylline [85], N-Acetylcysteine[86], and surfactant

Conflicting data exist about the evolution ARDS mortality
over time. A meta-analysis by Phua et al did not find any
mortality reduction in recent years [94], whereas another
meta-analysis by Zambon et al. showed reduced mortality
in recent years [4]. In the past, several studies evaluated patterns of ARDS mortality over time within the same institution [95-99], and all studies, except for two [98, 99], found
decreasing mortality in ARDS. The observed discrepancy
between different studies may be due to different investigational methods, but we can conclude that ARDS mortality
remains high (41 - 46%). Regardless of improvements in recent years, ARDS mortality is higher in older patients and in
medical patients [100]. However, the impact, if any, of newer
treatment strategies on ARDS mortality has not been evaluated, because most studies are referred to the period before
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the year 2000.
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